HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $14 price target.
August 08, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Inozyme Pharma and maintained a $14 price target.
The reiteration of a Buy rating and the maintenance of a $14 price target by a reputable analyst can boost investor confidence in Inozyme Pharma, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100